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Abstract 
Background: An increased frequency of psychotic disorders in Amyotrophic Lateral Sclerosis (ALS) 
families compared to controls has been reported. Aim of our study was to assess the relationship 
between nervous system drugs (NSD) prescriptions and subsequent onset of ALS in a large Italian 
population.  
Methods: The study population consisted of all subjects over 15 years old at the 2001 Italian census, 
resident in Turin since 1996 (n=687,324), followed up for ALS occurrence from 2002 to 2014. 
Exposure to NSD was measured until 2012, or until one year before ALS onset. The association of 
ALS with NSD was estimated for ever and cumulative exposure. Analyses were conducted through 
Cox proportional Hazards models adjusted for sex, age, education, marital status and drug co-
exposure.  
Results: In the analysis for ever exposure, Opioids were significantly inversely associated with ALS 
risk (HR=0.59), while Antiepileptics (HR=1.35) showed a marginally significantly positive 
association. Examining cumulative exposure, the protective role of Opiods associated with more than 
four prescriptions and the risk effect of Antiepileptics for over six prescriptions were confirmed. 
Conclusions: The present study revealed associations of ALS onset with previous exposure to Opioids 
and Antiepileptics, which are novel findings, to our knowledge, and should be further investigated. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of the motor system, 
characterized by muscular atrophy leading to death due to respiratory failure. During the trajectory of 
the disease, ALS patients experience progressive immobility and inability to speak, swallow and 
breathe. The median survival of ALS is 2-4 years from symptoms onset, while a period of 9-12 
months usually occurs from first symptoms to diagnosis [1].  
The mean annual incidence of ALS in Europe is estimated to be 2.08 (IQR 1.47-2.43) per 100,000 
population [2]. ALS incidence increases with age, with a peak in the seventh decade [2], slightly lower 
for familial than for sporadic ALS [3]. 
ALS is familial in about 10% cases and sporadic in the remaining 90% [4]. The findings in ALS 
genetics in the last years have had a significant impact in improving our knowledge on the molecular 
mechanisms of motor neuron degeneration, although the etiology of most sporadic ALS cases remains 
unknown [5]. The research on environmental exposure for ALS produced a large number of 
contributes, although findings were mixed and not consistent [1].  
A few recent studies, which focused on the potential role of the consumption of some drugs in ALS 
onset, have identified significant associations with centrally acting muscle relaxants (CAMRs), non-
steroidal anti-inflammatory drugs (NSAIDs) and anti-hypertensive drugs. In particular, the risk of 
ALS was found to be reduced among subjects with previous consumption of CAMRs [6] and of 
NSAID [7,8,9], and of Angiotensin-Converting Enzyme (ACE) inhibitors drugs [10]. 
Additionally, Antipsychotic and Antidepressant drugs have been hypothesized to be protective toward 
ALS onset [11], while some studies have shown an increased risk of psychotic manifestations and 
other neurodegenerative disorders associated in ALS patients and their family aggregates 
[12,13,14,15]. However, no longitudinal studies have been conducted on the association between ALS 
onset and previous nervous system drugs (NSD) consumption. 
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The aim of the present study was to assess whether drugs acting on nervous system could have an 
effect on the development of ALS. For this purpose, we analyzed the association between 
prescriptions of NSD and subsequent risk of developing ALS in a large Italian urban population.  
 
 
Materials and Methods 
 
Data collection 
The study population included all people older than 15 years, identified at 2001 Italian census and 
resident in the town of Turin (Italy) from January 1
st
 1996 (n=687,324). Baseline information on 
demographics, marital status and educational level was obtained from 2001 census data, which were 
linked, by means of a unique identification number, with the Municipality Registry, the ATC Drug 
Prescription Registry, and the Piedmont and Valle d’Aosta ALS Register (PARALS). The PARALS, 
established in 1995, is a prospective epidemiological register of ALS in two Italian regions (total 
population, 4,500,000 inhabitants) and has a very good level of completeness [16].  
Subjects were followed up for ALS occurrence from January 1
st
 2002 to December 31
st
 2014, or until 
the date of emigration out of Turin, death or ALS onset, defined as the time of motor symptoms onset. 
The outcome was represented by ALS onset, ascertained through the PARALS and recorded up to 
December 31
st
, 2014. Subjects diagnosed with ALS before the start of follow-up were excluded from 
the study (N= 92). 
NSD were extracted from the Piedmont Regional Drugs Registry, in which all drugs prescribed by 
medical doctors of the National Health Service (NHS) were registered since January 1
st
 1997. All 
drugs bought without NHS general practitioners’ prescriptions (e.g. over the counter drugs) are not 
included in the regional Drug Prescription Registry. NSD were identified through the presence of the 
macro-code “N” of the Anatomical Therapeutic Chemical (ATC) classification, a system developed by 
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the World Health Organization which classifies all drugs into definite groups, based on their 
therapeutic, pharmacological and chemical properties [17]. Some families of NSD were not considered 
because of the small numbers of subjects who were prescribed drugs belonging to these families, and 
because the Piedmont Regional Drug Registry does not include certain classes of drugs which cannot 
be prescribed through the Italian NHS, the most important being anxiolytics, hypnotics and sedatives.  
The association between ALS and drug prescriptions was explored for the following ATC families of 
NSD, up to the third level of classification: Opioids (N02A); Antiepileptic drugs (N03A); 
Antiparkinsonian drugs (N04); Antipsychotics (N05A); Antidepressants (N06A). 
The study was conducted using Italian administrative data under the frame of the National Plan of 
Statistics [18]. The record-linkage between administrative data (census, drug prescriptions and 
mortality data) and PARALS was performed in accordance with Italian regulations on the privacy and 
with the approval of the local ethical committee.  
 
Statistical analysis 
Exposure to NSD was measured from 1997 January 1
st
 until December 31
st
 2012 or, for ALS cases, 
until one year before the onset of the disease. Exposure to each drug family considered was treated as 
time-dependent variable, which changed at the date of every new prescription. A time-span dataset 
was then constructed in order to perform survival analysis: the first observation covered the time span 
from the entry into the study until the time of a new prescription, the second observation spans from 
the last prescription to the time of a second new prescription, and so on. 
The association between NSD consumption and ALS onset was assessed using Cox proportional 
Hazards models with robust standard errors. A first model was adjusted for age class (15-29, 30-44, 
45-59, 60-74, over 75 years), sex and prescription of NSD families other than the one examined. A 
second model was built adjusting also for educational level (primary, secondary, higher and graduate 
education) and marital status (married, unmarried and previously married).  
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The association of ALS with each class of NSD was estimated for both ever and cumulative exposure, 
using subjects without prescriptions as the reference category of the corresponding class of drugs. 
Ever exposure was defined as having at least one prescription of the corresponding drug family, while 
cumulative exposure as the number of prescriptions for each drug family, classified in three ordinal 
categories, built on the basis of the distribution of the exposed cases (unexposed, low and middle-high 
exposed, where low exposed corresponded to the first tertile of cumulative dose and middle-high to 
the second and the third tertiles).  
Furthermore, in order to explore whether the association of a certain drug family was attributable to 
specific drugs within this family, the relationship between ALS and ever exposure to specific active 
pharmaceutical ingredients with five or more ALS exposed cases was examined in a model controlled 
for age, sex, education and marital status. 
Last, a sensitivity analysis was performed, in which exposure to drugs was truncated two years before 
ALS onset, instead of one year, in order to limit the possibility that the association observed with ALS 
was actually attributable to their use as therapeutic agents for ALS at start of symptoms, although 
before its diagnosis (e.g. drugs consumption for pain therapy).  
 
 
Results 
 
Descriptive results 
During the follow-up period, 300 subjects resident in the town of Turin were diagnosed with ALS 
(165 men and 135 women). Descriptive statistics of the study population are presented in Table 1: 
distributions by sex, age, educational level and marital status are referred to the start of follow-up. 
Distributions of NSD prescriptions (Table 2) are instead referred to the whole follow-up period.  
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The mean ALS annual incidence in the study population over 15 years was 4.0 per 100,000 inhabitants 
(4.8 among men and 3.4 among women). As expected, an increasing trend of ALS rates with 
increasing age was observed until 75 years, with a strong increase above 45 years and only 6.4% of 
subjects with ALS onset below 45 years.  
With respect to the distribution of drugs prescriptions, ever exposure was most common for 
Antidepressant drugs (ALS cases: 25.3%, non-cases: 28.2%), followed by Opioids (ALS cases: 5.8%, 
non-cases: 18.5%) and Antiepileptics (ALS cases: 10.3%, non-cases: 11.1%), whereas for 
Antiparkinsonians and Antipsychotics the proportion of subjects with at least one prescription did not 
exceed 10%.  
 
TAB. 1  
TAB. 2  
 
In ALS cases, most common active ingredients in the Opioids family were Tramadol (61.0%) and 
Codeine and combinations (27.0%), while among Antiepileptics the most common was Gabapentin 
(49%) (Table 5, Online Resource).  
Among ALS cases, average latency between first drug prescription and clinical onset of ALS was 2.8 
years for Opioids, 5.6 years for Antiepileptics, 4.7 years for Antiparkinsonians, 7.2 years for 
Antipsychotics, and 5.7 years for Antidepressants. 
 
Association between NSD and ALS onset  
The associations of ALS with ever and cumulative exposure to the different drug families are shown in 
Tables 2 and 3. In both tables, Model 1 shows results adjusted for age, sex and drug co-exposure, and 
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Model 2 reports the results adjusted also for education and marital status. Since the results of Model 1 
and 2 were very similar, only the latter will be presented and commented in the text.  
In the fully adjusted model for ever exposure (Table 2), only Opioids were significantly associated 
with ALS risk and showed a protective effect (HR=0.59; 95% CI=0.35-0.97). A non-significant 
decrease of ALS risk was also observed for the exposure to Antiparkinsonian drugs (HR=0.62, 95% 
CI=0.27-1.40). Conversely, the prescription of Antiepileptics was associated with a non-significant 
increase of ALS risk (HR=1.35; 95% CI=0.92-2.00). For Antipsychotics and Antidepressants, Hazard 
Ratios were close to one and non-significant.  
When examining cumulative exposure (Table 3), in the fully adjusted model (Model 2) Opiods 
showed a significant decreasing trend in ALS risk across ordered increasing levels of cumulative 
exposure (test for trend: p=0.014), although only the highest exposure category was marginally 
significantly associated with ALS (HR=0.25; 95% CI=0.06-1.01). Cumulative exposure to 
Antiepileptics also showed a significant trend with increasing ALS risk (test for trend: p=0.040), but in 
the opposite direction: in this case, too, only the highest exposure category was marginally 
significantly associated with ALS (HR=1.84; 95% CI=0.99-3.42). Antidepressant drugs in the lower 
cumulative exposure category were also significantly associated with an increased ALS risk 
(HR=1.39, 95% CI: 1.02-1.90), although the risk was below one and non-significant for the highest 
one. No trend in risk or association with ALS was instead observed for any category of cumulative 
exposure to Antiparkinsonian or Antipsychotic drugs.  
 
TAB. 3 
TAB. 4 
 
When examining the associations with specific active ingredients, for none of the drugs examined a 
significant association with ALS was found, although the direction remained the same as for drug 
families. Among Opioids, HR for Tramadol was 0.60 (95% CI: 0.32-1.14) and for Codeine and 
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combinations was 0.52 (95% CI: 0.21-1.30). Regarding Antiepileptic drugs, the relative risk 
associated with Gabapentin was 1.52 (95% CI: 0.93-2.47).  
The results of the sensitivity analysis, in which drugs exposure was truncated two years before ALS 
onset, were similar to the previous ones, except for the loss of significance of the association observed 
between the risk of ALS and low cumulative exposure to Antidepressants (HR=1.28; 95% CI=0.94-
1.76). 
 
 
Discussion  
The present study found a protective effect of Opioids and a detrimental effect of Antiepileptics on the 
onset of ALS. The dose-response effect observed between ALS risk and cumulative exposure to these 
NSD families indicates that these associations may reflect a causal relationship. It is however 
uncertain whether these associations are actually attributable to the diseases for which these drugs 
were prescribed, rather than to detrimental or protective effects of the drugs themselves.  
In our cohort we found an increased exposure to Antiepileptics well before ALS onset (5.6 years on 
average). This observation may indicate that epilepsy is an antecedent phenomenon laying in the 
developing trajectory of the disease, in according with a previous observation that in a cohort of ALS 
patients the incidence of epilepsy was higher than in the general population [19]. A possible direct 
detrimental effect of Antiepileptic drugs on ALS onset cannot be excluded, although neuroprotective 
effects of Gabapentin and Valproic acid have been found in ALS mouse models [20,21], which were 
confirmed in clinical trials on humans [22,23].   
Concerning Opioids, it could well be that ALS patients experience pain during the onset period and be 
treated with these drugs in order to reduce it, but in this case Opioids consumption should be 
positively associated with ALS, in contrast with our findings. 
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The low risk associated with the high cumulative exposure category of Antidepressants suggests that 
the excess risk observed for the low cumulative exposure category is probably a fortuitous finding, 
considering that a great proportion of subjects in this category (40%) were prescribed Antidepressants 
only for a short period or even once, and it does not seem biologically plausible that such a low 
cumulative exposure could have had an influence on ALS development. Nonetheless, this finding 
appears consistent with the results of a recent study on ALS patients, which observed, more than one 
year before ALS diagnosis, a two-fold prevalence ratio of antidepressant use, compared to the general 
population [24]. A narrative review on the relationship between exposure to Antipsychotics and 
Antidepressants, and ALS onset has hypothesized that these drugs may reduce the risk of developing 
ALS [11].  
In this longitudinal study, prevalent cases have been excluded before start of follow-up allowing 
therefore to take into account the temporal sequence between drug exposure and ALS occurrence and 
to minimize the possibility of selection bias due to the short duration of the disease and. Several 
studies found associations of neurodegenerative and psychiatric disorders with ALS, but were not able 
to examine the temporal relation with ALS onset [12,13,14,15,19]. The type of analysis performed, i.e. 
survival analysis, which considers the exposure to drugs as time-dependent variables, has allowed to 
classify correctly exposed and non-exposed periods at the individual level and to compute 
appropriately exposed and non-exposed person-years.  
This study has some weakness. First, the exposure to the drugs was assessed for a relatively limited 
period, since data on lifetime exposure were not available. However, incomplete reconstruction of the 
history of the exposure to drugs might cause non-differential exposure misclassification, leading to an 
attenuation bias, which may explain null results for some drug families (such as Antiparkinsonian, 
Antipsychotic and Antidepressant drugs), but not the significant associations identified. Second, we 
could not include in the analysis as covariates life style habits, such as tobacco smoking, alcohol 
consumption, obesity or physical activity, although among these only smoking has been consistently 
associated with ALS [25]. However, adjustment for educational level should have at least partly 
controlled for differences in smoking habits between exposed and non-exposed groups.  
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Conclusion 
The present study was performed in order to evaluate the association between previous consumption 
of NSD and ALS onset in a large Italian population. Opioids and Antiepileptics played a significant 
role on the onset of ALS: the former played a protective role on developing ALS disease, while the 
latter showed a detrimental effect. No significant effects were found for Antiparkinsonian, 
Antipsychotic and Antidepressant drugs. These associations between the drugs of nervous system and 
the onset of ALS represent a novel finding, which should be further investigated.  
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TABLES 
Table 1. Frequency distribution of sex, age, educational level and marital status at start of follow-up 
in ALS cases, non-cases and total populations. 
 Non-ALS  
population 
ALS  
Population 
Total  
population 
 N % N % N % 
Sex       
male 319,911 46.6 165 55.0 320,076 46.6 
female 367,113 53.4 135 45.0 367,248 53.4 
Age       
15-29 years 114,640 16.7 2 0.7 114,642 16.7 
30-44 years 165,873 24.1 17 5.7 165,890 24.1 
45-59 years 164,951 24.0 101 33.6 165,052 24.0 
60-74 years 165,743 24.2 153 51.0 165,896 24.2 
over 75 years 75,817 11.0 27 9.0 75,844 11.0 
educational level       
no school or elementary school 181,430 26.4 92 30.7 181,522 26.4 
middle school 231,910 33.8 92 30.7 232,002 33.7 
high school 196,168 28.5 79 26.3 196,247 28.6 
graduation 77,516 11.3 37 12.3 77,553 11.3 
marital status       
married 380,305 55.4 210 70.0 380,515 55.4 
unmarried 188,650 27.4 31 10.3 188,681 27.4 
previously married 118,069 17.2 59 19.7 118,128 17.2 
Total 687,024 100.0 300 100.0 687,324 100.0 
 
Table 2. Frequency distribution of nervous system drugs prescriptions (categorical cumulative dose 
classified in tertiles) at end of follow-up in ALS cases, non-cases and total populations. 
 Non-ALS  ALS  Total  
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Population Population population 
 N % N % N % 
Opioids– N02A       
no prescriptions 560,112 81.5 282 94.0 560,394 81.5 
I tertile (up to 3) 46,776 6.8 10 3.3 46,786 6.8 
II tertile (4 – 14) 39,428 5.8 4 1.3 39,432 5.8 
III tertile (over 15) 40,708 5.9 4 1.4 40,712 5.9 
Antiepileptics – N03A       
no prescriptions 610,613 88.9 269 89.7 610,882 88.9 
I tertile (up to 6) 25,672 3.7 16 5.3 25,688 3.7 
II tertile (7 – 35) 25,556 3.7 8 2.7 25,564 3.7 
III tertile (over 36) 25,183 3.7 7 2.3 25,190 3.7 
Antiparkinsons – N04       
no prescriptions 661,470 96.3 294 98.0 661,764 96.3 
I tertile (up to 14) 8,676 1.3 2 0.7 8,678 1.3 
II tertile (15 – 65) 8,378 1.2 3 1.0 8,381 1.2 
III tertile (over 66) 8,500 1.2 1 0.3 8,501 1.2 
Antipsychotics – N05A       
no prescriptions 624,432 90.9 275 91.7 624,707 90.9 
I tertile (up to 8) 22,085 3.2 10 3.3 22,095 3.2 
II tertile (9 – 41) 19,918 2.9 9 3.0 19,927 2.9 
III tertile (over 42) 20,589 3.0 6 2.0 20,595 3.0 
Antidepressants –  N06A       
no prescriptions 493,221 71.8 224 74.7 493,445 71.8 
I tertile (up to 4) 68,777 10.0 41 13.7 68,818 10.0 
II tertile (5 – 21) 61,641 9.0 16 5.3 61,657 9.0 
III tertile (over 22) 63,385 9.2 19 6.3 63,404 9.2 
Total 687,024 100.0 300 100.0 687,324 100.0 
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Table 3. Hazard Ratios (HR) of ALS onset associated with nervous system drugs prescriptions 
distinguished by drug family (ATC) and ever exposure – Cox proportional Hazards models adjusted 
for age
a
, sex, drug co-exposure (Model 1), and also education
b
 and marital status
c
 (Model 2). Robust 
standard errors. 
 Model 1 Model 2 
 HR 95% CI HR 95% CI 
no prescriptions 1 - 1 - 
Opioids (N02A) 0.56 0.34-0.93 0.59 0.35-0.97 
Antiepileptics (N03A) 1.33 0.91-1.96 1.35 0.92-2.00 
Antiparkinsons (N04) 0.61 0.28-1.39 0.62 0.27-1.40 
Antipsychotics (N05A) 0.98 0.64-1.52 0.99 0.64-1.54 
Antidepressants (N06A) 1.15 0.86-1.54 1.14 0.85-1.53 
a
 age in 5 classes: 15-29, 30-44, 45-59, 60-74, over 75; 
b
 education in 4 classes: no school or elementary school, middle school, high school and graduation; 
c
 marital status in 3 classes: married, unmarried and previously married; 
 
Table 4. Hazard Ratios (HR) of ALS onset associated with nervous system drugs prescriptions 
distinguished by drug family (ATC) and categorical cumulative dose – Cox proportional Hazards 
models adjusted for age
a
, sex, drug co-exposure (Model 1), and also education
b
 and marital status
c
 
(Model 2). Robust standard errors. 
 Model 1 Model 2 
 HR 95% CI IRR 95% CI 
Opioids (N02A)     
no prescriptions 1 - 1 - 
I tertile (up to 3) 0.68 0.40-1.16 0.71 0.42-1.21 
II & III tertiles (over 4) 0.24 0.06-0.96 0.25 0.06-1.01 
Antiepileptics (N03A)     
no prescriptions 1 - 1 - 
I tertile (up to 6) 1.25 0.80-1.96 1.27 0.81-1.99 
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II & III tertiles (over 7) 1.80 0.97-3.34 1.84 0.99-3.42 
Antiparkinsons (N04)     
no prescriptions 1 - 1 - 
I tertile (up to 14) 0.62 0.22-1.72 0.63 0.23-1.73 
II & III tertiles (over 15) 0.72 0.18-2.88 0.72 0.18-2.87 
Antipsychotics (N05A)     
no prescriptions 1 - 1 - 
I tertile (up to 8) 1.10 0.69-1.76 1.12 0.70-1.78 
II & III tertiles (over 9) 0.93 0.38-2.31 0.95 0.38-2.35 
Antidepressants (N06A)     
no prescriptions 1 - 1 - 
I tertile (up to 4) 1.40 1.03-1.91 1.39 1.02-1.90 
II &III tertiles (over 5) 0.78 0.49-1.24 0.76 0.48-1.21 
a
 age in 5 classes: 15-29, 30-44, 45-59, 60-74, over 75; 
b
 education in 4 classes: no school or elementary school, middle school, high school and graduation; 
c
 marital status in 3 classes: married, unmarried and previously married;  
 
 
ONLINE ONLY 
 
Table 5. Frequency distribution of ATC drugs prescriptions codes and active ingredients in ALS cases, 
non-cases and total populations.  
ATC code Active ingredient 
Non-ALS 
population 
ALS population Total population 
N % N % N % 
N02AA01 Morphine  5,041 4.0% 1 5.6% 5,042 4.0% 
N02AA03 Hydromorphone  329 0.3% 0 0.0% 329 0.3% 
N02AA05 Oxycodone  1,297 1.0% 0 0.0% 1,297 1.0% 
N02AA55 Oxycodone, combinations  1,147 0.9% 0 0.0% 1,147 0.9% 
N02AA59 Codeine, combinations excl. 51,167 40.3% 5 27.8% 51,172 40.3% 
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psycholeptics  
N02AA99 Various associations 5,277 4.2% 0 0.0% 5,277 4.2% 
N02AB03 Fentanyl  5,735 4.5% 1 5.6% 5,736 4.5% 
N02AC02 Methadone 4 0.0% 0 0.0% 4 0.0% 
N02AD01 Pentazocine  35 0.0% 0 0.0% 35 0.0% 
N02AE01 Buprenorphine 2,063 1.6% 0 0.0% 2,063 1.6% 
N02AG01 Morphine and antispasmodics  6 0.0% 0 0.0% 6 0.0% 
N02AX02 Tramadol  54,405 42.9% 11 61.1% 54,416 42.9% 
N02AX06 Tapentadol  389 0.3% 0 0.0% 389 0.3% 
N02AX52 Tramadol, combinations 17 0,0% 0 0,0% 17 0,0% 
Total N02A – Opioids 126,912 100.0% 18 100.0% 126,930 100.0% 
       
N03AA02 Phenobarbital 4,943 6.5% 2 6.5% 4,945 9.0% 
N03AA03 Primidone  503 0.7% 0 0.0% 503 0.9% 
N03AA04 Barbexaclone  485 0.6% 2 6.5% 487 0.9% 
N03AB02 Phenytoin 655 0.9% 0 0.0% 655 1.2% 
N03AB52 Phenytoin, combinations 1 0.0% 0 0.0% 1 0.0% 
N03AD01 Ethosuximide  30 0.0% 0 0.0% 30 0.1% 
N03AE01 Clonazepam  3,045 4.0% 1 3.2% 3,046 5.5% 
N03AF01 Carbamazepine  10,165 13.3% 3 9.7% 10,168 18.4% 
N03AF02 Oxcarbazepine 1,803 2.4% 3 9.7% 1,806 3.3% 
N03AF03 Rufinamide  1 0.0% 0 0.0% 1 0.0% 
N03AG01 Valproic acid  8,004 10.5% 1 3.2% 8,005 14.5% 
N03AG02 Valpromide  241 0.3% 0 0.0% 241 0.4% 
N03AG04 Vigabatrin  169 0.2% 0 0.0% 169 0.3% 
N03AG06 Tiagabine  9 0.0% 0 0.0% 9 0.0% 
N03AG99 Various associations 1 0.0% 0 0.0% 1 0.0% 
N03AX09 Lamotrigine 1,083 1.4% 0 0.0% 1,083 2.0% 
N03AX10 Felbamate 5 0.0% 0 0.0% 5 0.0% 
N03AX11 Topiramate 1,323 1.7% 0 0.0% 1,323 2.4% 
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N03AX12 Gabapentin 23,545 30.8% 15 48.4% 2,356 4.3% 
N03AX14 Levetiracetam 1,012 1.3% 1 3.2% 1,013 1.8% 
N03AX15 Zonisamide 3 0.0% 0 0.0% 3 0.0% 
N03AX16 Pregabalin 19,383 25.4% 3 9.7% 19,386 35.1% 
N03AX18 Lacosamide  2 0.0% 0 0.0% 2 0.0% 
Total N03A – Antiepileptics 76,411 100.0% 31 100.0% 76,442 100.0% 
        
N04AA01 Trihexyphenidyl  179 1.3% 0 0.0% 179 0.8% 
N04AA02 Biperiden  4,811 35.0% 0 0.0% 4,811 20.5% 
N04AA03 Metixene  237 1.7% 0 0.0% 237 1.0% 
N04AA04 Procyclidine  61 0.4% 0 0.0% 61 0.3% 
N04AA11 Bornaprine  390 2.8% 0 0.0% 390 1.7% 
N04AB02 Orphenadrine (chloride) 231 1.7% 0 0.0% 231 1.0% 
N04BA01 Levodopa 3 0.0% 0 0.0% 3 0.0% 
N04BA02 
Levodopa and decarboxylase 
inhibitor  1,083 7.9% 2 33.3% 10832 46.1% 
N04BA03 
Levodopa, decarboxylase 
inhibitor and COMT inhibitor  14 0.1% 0 0.0% 14 0.1% 
N04BA04 Melevodopa  1 0.0% 0 0.0% 1 0.0% 
N04BA05 
Melevodopa and decarboxylase 
inhibitor 390 2.8% 0 0.0% 390 1.7% 
N04BB01 Amantadine  2 0.0% 0 0.0% 2 0.0% 
N04BC00 Other dopamine agonists 231 1.7% 0 0.0% 231 1.0% 
N04BC01 Bromocriptine 419 3.1% 0 0.0% 419 1.8% 
N04BC02 Pergolide  251 1.8% 0 0.0% 251 1.1% 
N04BC04 Ropinirole  508 3.7% 1 16.7% 509 2.2% 
N04BC05 Pramipexole  3,954 28.8% 3 50.0% 3,957 16.9% 
N04BC06 Cabergoline  436 3.2% 0 0.0% 436 1.9% 
N04BC07 Apomorphine  6 0.0% 0 0.0% 6 0.0% 
N04BC09 Rotigotine  83 0.6% 0 0.0% 83 0.4% 
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N04BC49 Various associations 150 1.1% 0 0.0% 150 0.6% 
N04BD01 Selegiline  230 1.7% 0 0.0% 230 1.0% 
N04BD02 Rasagiline  48 0.3% 0 0.0% 48 0.2% 
N04BX01 Tolcapone 3 0.0% 0 0.0% 3 0.0% 
N04BX02 Entacapone 7 0.1% 0 0.0% 7 0.0% 
Total N04 – Antiparkinsians 25,554 100.0% 6 100.0% 25,560 100.0% 
        
N05AA01 Chlorpromazine 1,771 3.1% 1 4.0% 1,772 2.9% 
N05AA02 Levomepromazine  314 0.5% 0 0.0% 314 0.5% 
N05AA03 Promazine  40 0.1% 0 0.0% 40 0.1% 
N05AB01 Dixyrazine  50 0.1% 0 0.0% 50 0.1% 
N05AB02 Fluphenazine  199 0.3% 0 0.0% 199 0.3% 
N05AB03 Perphenazine  23 0.0% 0 0.0% 23 0.0% 
N05AB06 Trifluoperazine  54 0.1% 0 0.0% 54 0.1% 
N05AC01 Periciazine  1,367 2.4% 0 0.0% 1,367 2.2% 
N05AC02 Thioridazine  161 0.3% 0 0.0% 161 0.3% 
N05AC99 Other Phenothiazines  2 0.0% 0 0.0% 2 0.0% 
N05AD01 Haloperidol  9,402 16.3% 5 20.0% 9,407 15.4% 
N05AD05 Pipamperone  15 0.0% 0 0.0% 15 0.0% 
N05AD06 Bromperidol 275 0.5% 0 0.0% 275 0.4% 
N05AE04 Ziprasidone 3 0.0% 0 0.0% 3 0.0% 
N05AF02 Clopenthixol  9 0.0% 0 0.0% 9 0.0% 
N05AF05 Zuclopenthixol  34 0.1% 0 0.0% 34 0.1% 
N05AG02 Pimozide  259 0.4% 0 0.0% 259 0.4% 
N05AH02 Clozapine  462 0.8% 0 0.0% 462 0.8% 
N05AH03 Olanzapine  3,268 5.7% 0 0.0% 3,268 5.3% 
N05AH04 Quetiapine  211 0.4% 2 8.0% 2,112 3.5% 
N05AH06 Clotiapine  1,868 3.2% 1 4.0% 1,869 3.1% 
N05AL00 Other benzamides 168 0.3% 1 4.0% 1,681 2.7% 
N05AL01 Sulpiride  989 1.7% 0 0.0% 989 1.6% 
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N05AL03 Tiapride  1,916 3.3% 0 0.0% 1,916 3.1% 
N05AL05 Amisulpride  27,542 47.7% 12 48.0% 27,554 45.0% 
N05AL07 Levosulpiride  355 0.6% 0 0.0% 355 0.6% 
N05AL49 Various associations 1,495 2.6% 1 4.0% 1,496 2.4% 
N05AN01 Lithium 2,004 3.5% 1 4.0% 2,005 3.3% 
N05AX08 Risperidone 3,281 5.7% 1 4.0% 3,282 5.4% 
N05AX12 Aripiprazole  159 0.3% 0 0.0% 159 0.3% 
N05AX13 Paliperidone  36 0.1% 0 0.0% 36 0.1% 
Total N05a – Antipsychotics 62,592 100.0% 25 100.0% 62,617 100.0% 
        
N06AA01 Desipramine  120 0.1% 0 0.0% 120 0.1% 
N06AA02 Imipramine  721 0.4% 0 0.0% 721 0.4% 
N06AA04 Clomipramine  4,955 2.6% 5 6.6% 496 0.3% 
N06AA05 Opipramol  25 0.0% 0 0.0% 25 0.0% 
N06AA06 Trimipramine 152 0.1% 0 0.0% 152 0.1% 
N06AA09 Amitriptyline  24,957 13.1% 9 11.8% 24,966 14.1% 
N06AA10 Nortriptyline  536 0.3% 0 0.0% 536 0.3% 
N06AA15 Butriptyline  3 0.0% 0 0.0% 3 0.0% 
N06AA19 Amineptine  2,975 1.6% 1 1.3% 2,976 1.7% 
N06AB03 Fluoxetine  12,487 6.6% 3 3.9% 1,249 0.7% 
N06AB04 Citalopram  36,466 19.2% 12 15.8% 36,478 20.7% 
N06AB05 Paroxetine  37,756 19.8% 18 23.7% 37,774 21.4% 
N06AB06 Sertraline  24,016 12.6% 8 10.5% 24,024 13.6% 
N06AB08 Fluvoxamine 2,137 1.1% 1 1.3% 2,138 1.2% 
N06AB10 Escitalopram  14,107 7.4% 4 5.3% 14,111 8.0% 
N06AX03 Mianserin  201 0.1% 1 1.3% 2,011 1.1% 
N06AX05 Trazodone  14,283 7.5% 8 10.5% 14,291 8.1% 
N06AX09 Viloxazine 44 0.0% 0 0.0% 44 0.0% 
N06AX11 Mirtazapine  2,522 1.3% 1 1.3% 2,523 1.4% 
N06AX12 Bupropion  239 0.1% 0 0.0% 239 0.1% 
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N06AX16 Venlafaxine  8,707 4.6% 4 5.3% 8,711 4.9% 
N06AX18 Reboxetine  182 0.1% 0 0.0% 182 0.1% 
N06AX21 Duloxetine  2,726 1.4% 1 1.3% 2,727 1.5% 
N06AX22 Agomelatine  1 0.0% 0 0.0% 1 0.0% 
N06AX49 Desipramine  38 0.0% 0 0.0% 38 0.0% 
Total N06a – Antidepressants 193,803 100.0% 76 100.0% 193.879 100.0% 
 
 
 
